



# Readily-available stocks of formulated FMD vaccine and/or inactivated antigen for emergency use in EUFMD member countries

Results of a questionnaire survey  
ran by the EuFMD (Function IV, 7)



# Responses

Sent out to EuFMD  
& neighbouring countries (47)

31 replies received  
(25 EuFMD member states)



# Summary of questionnaire

- National arrangements for supply of Antigen/Formulated vaccine: 9 (6 EuFMD members)
- 8 National banks held in a vaccine producing company
- 2 banks held in a national vaccine bank
- Mostly inactivated FMD antigens, but also some formulated vaccine



# Summary of questionnaire

3 EuFMD (non EU) member countries don't have any arrangement for supply of vaccine/Ag

1 EuFMD neighbouring country does not have any arrangement for supply of vaccine/Ag

Agreement with IGVB: 27 (all EUVB) plus Norway + Croatia



# National inactivated FMD Ag stocks

- 9 countries reported to have own NVB \*
- All high priority strains identified by WRL covered
- Few medium priority strains are included
- Even less low priority and/or other strains

(\*1 EuFMD member state has stopped keeping a NVB, responses pending from another 2 EuFMD MS , who keep NVBs)



## WRL high priority strains

(at least one in each bank, in most cases more than 3)

Serotype	O Manisa	O Panasia 2	O BFS or Campos	A-Iran- 05*	A24 Cruzeiro	A22 Iraq	Asia 1 Shamir	SAT 2 Saudi Arabia ( <i>or equivalent</i> )
Nb banks	7	3	1	7	1	3	8	5

Total: **51,52 million doses**, excluding the EUVB

Majority >2,5 million doses

Few < 1 million

Last survey (2011), Total : **72,75 million doses**, excluding the EUVB

*Note: replies pending from 2 countries that previously reported vaccine banks (  $\simeq$  13.5 million additional doses in the last survey)*



# Vaccine/antigen availability per FMDV pool

*(Note: some strains are present in more than one pool)*

FMDV Pool	% of doses, from all vaccine or antigen banks collectively, that could be used (theoretically) for strains within the same pool
1 (Central /East Asia)	20,54 %
2 (South Asia)	20,54 %
3 (West Eurasia & Middle East)	79,21 %
4 (Eastern Africa)	0,00 %
5 (West/Central Africa)	4,43 %
6 (Southern Africa)	4,95 %
7 (South America)	7,18 %



# Issues

## **Mechanisms to sell:**

- **To EuFMD?**
- **To others?**

**EuFMD has 150.000 doses (trivalent vaccine)**

**Relation of European vaccine bank managers to each – other and to the international vaccine bank network (Pillar 1 ?)**

**In 2012 EuFMD contacted the European Vaccine Bank holders, following the Egypt crisis and one was willing to sell vaccine stock if needed.**





# THANKS FOR YOUR ATTENTION !!!